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Background: Provoked vestibulodynia (PVD) is a pain disorder localized in the vestibular mucosa. It is the most
common cause of dyspareunia among young women and it is associated with general pain hypersensitivity and
other chronic pain conditions. Polymorphism in the guanosine triphosphate cyclohydrolase (GCH1) gene has been
found to influence general pain sensitivity and the risk of developing a longstanding pain condition. The aim of this
study was to investigate GCH1-polymorphism in women with PVD and healthy controls, in correlation to pain
sensitivity.
Results: We found no correlation between the previously defined pain-protective GCH1-SNP combination and the
diagnosis of PVD. Nor any correlation with pain sensitivity measured as pressure pain thresholds on the arm, leg
and in the vestibule, coital pain scored on a visual analog scale and prevalence of other bodily pain conditions
among women with PVD (n = 98) and healthy controls (n = 102). However, among patients with current treatment
(n = 36), there was a significant interaction effect of GCH1-gene polymorphism and hormonal contraceptive (HC)
therapy on coital pain (p = 0.04) as well as on pressure pain thresholds on the arm (p = 0.04). PVD patients carrying
the specified SNP combination and using HCs had higher pain sensitivity compared to non-carriers. In
non-HC-users, carriers had lower pain sensitivity.
Conclusions: The results of this study gave no support to the hypothesis that polymorphism in the GCH1-gene
contributes to the etiology of PVD. However, among patients currently receiving treatment an interaction effect of
the defined SNP combination and use of hormonal contraceptives on pain sensitivity was found. This finding offers
a possible explanation to the clinically known fact that some PVD patients improve after cessation of hormonal
contraceptives, indicating that PVD patients carrying the defined SNP combination of GCH1 would benefit from this
intervention.
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Provoked vestibulodynia (PVD) is the most common
cause for superficial dyspareunia in young women, with
a prevalence of 13-15% [1]. PVD is a localized pain dis-
order [2] characterized by pain provoked by touch, pres-
sure and stretch of the tissue around the vaginal
opening often resulting in inability to engage in vaginal
intercourse. The condition can be divided into primary
PVD, defined as pain ever since first tampon use or vagi-
nal intercourse and secondary PVD, where dyspareunia
appears after a period of pain-free sexual intercourse [3].* Correspondence: ulrika.heddini@ds.se
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reproduction in any medium, provided the orThe etiology of PVD is still unclear and both biomedical
and psychosexual triggers are being discussed [4-9].
The pain mechanisms involved in PVD are not fully
understood. Studies have shown an increase of free
nerve endings, immuno-positive for the neurotransmit-
ters calcitonin gene-related peptide (CGRP) and sub-
stance P (SP), as well as an increased local blood flow in
the mucosa around the vaginal opening [10-12]. The
nerves are of sensory origin and are sensitized with low
pain thresholds for most stimuli suggesting a chronic
neurogenic inflammation [13,14]. There is also evidence
of involvement of central pain mechanisms. Women
with PVD have lower pain thresholds also in other body
areas and more concomitant bodily pain compared to
controls [15-17]. In addition, correlations to other painl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinical data
Variables Patients Controls p-value
(n = 98) (n = 102)
Current age, years 29 (19–44) 24 (18–35) <0.001
Duration of PVD, years 8 (0,5-18) - -
Primary PVD 35 (36%) - -
Secondary PVD 63 (64%) - -
Current use of hormonal contraceptives 33 (34%) 53 (52%) 0.005
Combined hormonal contraceptives 26 (27%) 42 (40%) ns
Progestogen only contraceptives 7 (7%) 11 (11%) ns
Menstrual cycle day 7.9 (4–13) 8.0 (3–13) ns
Concomitant pain
Dysmenorrhea 67 (71%) 55 (54%) 0.02
Headache 59 (60%) 30 (29%) <0.001
GI pain and dysfunction 53 (54%) 22 (22%) <0.001
Back pain 48 (49%) 20 (20%) <0.001
Muscle pain 31 (32%) 2 (2%) <0.001
Other pain 26 (27%) 1 (1%) <0.001
PVD=provoked vestibulodynia, GI = gastro-intestinal.
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drome have been reported [4,18].
A familial aggregation of PVD has not been proved, al-
though it has been found in other pain syndromes as-
sociated with PVD [19,20]. A limited number of studies
have investigated a possible genetic predisposition to
develop PVD, focusing on polymorphism in genes in-
volved in the pro-inflammatory immune-response [21-25].
There are an increasing number of studies on genetic
polymorphism influencing endogenous pain modulation
but this has not been studied among women with PVD.
Tegeder and colleagues have reported that specific single
nucleotide polymorphisms (SNPás) in the guanosine tri-
phosphate cyclohydrolase (GCH1) gene are associated
with reduced pain sensitivity in humans [26]. GCH1 is
the rate limiting enzyme in the biosynthesis of 6(R)-L-
erythro-5,6,7,8-tetrahydrobiopterin (BH4). BH4 is an
essential cofactor in the synthesis of several pain mod-
ulators including catecholamines, serotonin and nitric
oxide. BH4 regulates the activity of GCH1 via feed-
forward activation of phenylalanine and feedback inhib-
ition. The identified pain-protective SNP combination
of GCH1 is composed of 15 SNPás found at different
locations on the gene. Screening for three of these
SNPás has been shown to be a reliable way to identify
the pain-protective SNP combination with high sensi-
tivity and specificity [27]. Subsequently, several studies
have linked GCH1-polymorphism to various aspects of
pain including neuropathic and inflammatory pain,
whereas others have not [28-35]. A recent study inves-
tigating a possible association between different SNP
combinations in the GCH1-gene and a number of pain
behavior related outcomes during labor indicated a very
limited effect [36].
Many pain conditions, such as tension headache and
fibromyalgia are more prevalent in women than in men.
The possible effect of sex hormones on pain sensitivity
has been investigated in several studies [37,38]. There is
evidence suggesting that estrogens influence pain modu-
lation, however, both pro- and anti-nociceptive effects
have been found. For some stimuli, lower pain sensitivity
has been found during the follicular phase compared to
the luteal phase in normally menstruating women, al-
though inconsistent results exists [39-41].
In this study we aimed to investigate whether poly-
morphism in the GCH1-gene is related to PVD, hy-
pothesizing that the pain-protective SNP combination
previously identified would be less frequent among
women with PVD. Another aim was to explore possible
correlations between GCH1-polymorphism and vestibu-
lar and general pain sensitivity in women with PVD and
in healthy controls, including analyzes of a possible
interaction between the studied SNP combination and
use of hormonal contraceptives (HCs).Results
Clinical data
Clinical data of participants are shown in Table 1. In the
patient group, 60 participants had completed their treat-
ment and 38 were currently receiving treatment for
PVD. For participants who had completed their treat-
ment the median time since completion was 5 years
(range 2 months-11 years). Among patients with current
treatment 41% were using HCs and among those with
completed treatment 30%, with no significant difference.
Genotyping
Genotyping for the studied SNP combination of GCH1-
gene was completed in 200 subjects; 98 patients and 102
controls. The SNP frequencies in the total sample were:
dbSNP rs8007267G>A: GG=134 (67%), AG 60 (30%) and
AA=6 (3%); dbSNP rs3783641A>T: AA=129 (64.5%),
AT=62 (31%) and TT=9 (4.5%); dbSNP rs10483639C>G:
CC 129 (65%), CG+GC 61 (31%) and GG 9 (5%). The fre-
quencies of the different SNPs were in accordance with the
Hardy-Weinberg equilibrium (dbSNP rs8007267G>A:
χ2 =0.03, p= 0.870; dbSNP rs3783641A>T: χ2 =0.1,
p =0.755; dbSNP rs10483639C>G: χ2 =0.09, p= 0.762).
Individuals were classified as homozygous, heterozy-
gous or non-carriers of the specified SNP combination
according to Lötsch et al. [27]. The frequencies of the
SNP combinations are shown in Table 2.
SNP combinations in relation to PVD
There were no differences in the SNP frequency among
the patients (current and completed treatment together
Table 2 Carrier frequencies of the specified SNP combination of GCH1
Non carriers Homozygos carriers Heterozygos carriers
All participants (n = 200) 139 (70%) 5 (2%) 56 (28%)
Patients (n = 98) 70 (71%) 3 (3%) 25 (26%)
- current treatment (n = 38) 28 (73%) 1 (3%) 9 (24%)
-completed treatment (n = 60) 42 (70%) 2 (3%) 16 (27%)
Controls (n = 102) 69 (68%) 2 (2%) 31 (30%)
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ences in SNP carrier frequency between patients with
primary or secondary PVD.
Pain measurements
There were significantly higher pressure pain thresholds
(PPTs) on the arm and leg among controls compared to
patients with current treatment as well as to the patient
group as a whole (p = 0.002). Moreover, controls had
lower self-reported bodily pain scores. Among patients
with current treatment there were significantly higher
scores in coital VAS pain and lower PPTs in the vestibu-
lar area B compared to patients with completed treat-
ment. See Table 3.
There were no significant differences in PPTs on the
arm or leg between patients, controls or all participants
together using HCs or not. Among patients there were
no differences in vestibular PPTs, coital VAS pain or
bodily pain score between users and non-users of HCs.
Nor when users of combined or progestogen only HCs
were analyzed separately.
SNP combinations in relation to pain sensitivity
Due to the low number of individuals homozygous for
the SNP combination, both homozygous and heterozy-
gous individuals were merged into one group which was
contrasted to non-carriers.
There were no differences in PPTs, bodily pain score
or coital VAS pain between carriers or non-carriers of
the defined SNP combination among patients andTable 3 Pain measurements
Current treatment (n = 38) Completed treatmen
Mean (SD) Median (Q1-Q3) Mean (SD) Median
PPT leg (kPa) 389 (156) 377 (279–454) 417 (164) 403 (31
PPT arm (kPa) 249 (102) 215 (190–288) 279 (136) 248 (18
PPT vestibulum A (g) 43 (28) 30 (23–60) 51 (33) 46 (25–
PPT vestibulum B (g) 27 (19) 20 (13–38) 51 (53) 34 (20–
Coital VAS pain
(0–100)
71 (22) 73 (56–88) 40 (31) 28 (17–
Bodily pain score
(0–5)
2.1 (1.3) 2 (1–3) 2.1 (1.2) 2 (1–3)
PPT = Pressure pain threshold, kPa = kilopascal, A = anterior vestibule, B = posterior v
Whitney U-test.controls analyzed separately, or in the total sample ana-
lyzed together.Interaction effect of GCH1-polymorphism and use of HCs
on pain sensitivity
Among all patients analyzed together there was a trend
for an association between the specified SNP combin-
ation of GCH1 and use of HCs in relation to coital VAS
pain score (p < 0.07) with a low explained variance. How-
ever, when patients with current treatment were ana-
lyzed separately, there were significant main effects of
the GCH1-gene variants, as well as significant inter-
action effect with HC use. The combined effect of
GCH1-SNP combination and HC use explained approxi-
mately 8% of the variance in reported coital VAS pain,
see Table 4. Among patients with current treatment not
using HCs (n = 23) carriers of the specified GCH1-SNP
combination reported lower coital VAS pain compared
to non-carriers. On the other hand, in the group using
HCs (n = 15), carriers of the SNP combination reported
higher coital VAS pain, as shown in Figure 1.
To further explore the association between the SNP
combination and HC use in relation to the other mea-
sures of pain a series of general linear regression models
(GLMás) were performed, including PPTs on the arm,
leg, in vestibular area A and B and bodily pain score. In
the total sample of both patients and controls together
we found no association, nor in the patient group as a
whole. However, separate analysis of patients with
current treatment showed a relation between the GCH1-t (n = 60) Controls (n = 102) P-value
(Q1-Q3) Mean (SD) Median (Q1-Q3)
6–513) 475 (152) 457 (363–575) 0.006 (ANOVA), 0.004 (K-W)
8–335) 309 (116) 298 (227–355) 0.028 (ANOVA), 0.004 (K-W)
64) - - ns
70) - - <0.002 (t-test), <0.05 (M-WU)
68) - - <0.001 (t-test), <0.05 (M-WU)
0.8 (0.9) 1 (0–1) <0.001 (ANOVA), <0.001 (K-W)
estibule, VAS = visual analogue scale, K-W=Kruskal-Wallis test, M-WU=Mann–
Table 4 Linear regression analyses of association between GCH1-SNP combination and hormonal contraceptives use
among patients with current treatment (n =36)
Coital VAS pain score
df F p
GCH1-SNP combination 1 4.71 .037*
Hormonal contraceptives use 1 .11 .726
GCH1- SNP combination *hormonal contraceptives use 1 4.69 .038*
Adj R2 = 0.084
PPT arm
df F p
GCH1- SNP combination 1 4.64 .039*
Hormonal contraceptives use 1 1.49 .233
GCH1- SNP combination *hormonal contraceptives use 1 4.632 .039*
Adj R2 = 0.054
PPT leg
df F p
GCH1- SNP combination 1 3.92 .056
Hormonal contraceptives use 1 2.21 .147
GCH1- SNP combination *hormonal contraceptives use 1 3.90 .057
Adj R2 = 0.058
SNP= single nucleotide polymorphism, VAS = visual analogue scale, PPT = pressure pain threshold.
Figure 1 Interaction effect of the studied SNP combination of GCH1 and use of hormonal contraceptives (HCs) on coital pain among
patients currently receiving treatment (n = 38). VAS= visual analogue scale.
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a borderline significant relation to PPTs on the leg.
The relation between the GCH1-SNP combination, use
of HCs and PPTs on the arm is shown in Figure 2.
Among patients with current treatment not using HCs
(n = 23), carriers of the specified GCH1-SNP combin-
ation reported lower pain sensitivity (higher PPTs) on
the arm compared to non-carriers. Among patients
using HCs (n = 15) the picture is inversed with higher
pain sensitivity (lower PPTs) among carriers of the SNP
combination.
Discussion
The pain mechanisms involved in PVD remain an en-
igma. We hypothesized that the SNP combination of
GCH1 previously defined as pain protective would be
less frequent among PVD patients compared to healthy
controls, thus possibly contributing to the etiology of
the condition. However, we found the same carrier-
frequency of the different SNP combinations in patients
and controls. There are several possible explanations to
this lack of association. First of all pain is a very complex
sensation influenced by many factors, in this case bio-
medical as well as psychological and sexual. The influ-
ence of a single gene polymorphism is thereforeFigure 2 Interaction effect of the studied SNP combination of GCH1 a
thresholds (PPTs) on the arm among patients currently receiving treaexpected to be modest and difficult to statistically estab-
lish. Another possibility is that the observed pain in
PVD is regulated by other aspects of the endogenous
pain modulation not involving the BH4-pathway.
The studied GCH1-SNP combination has previously
been associated with protection from the development
of chronic pain after surgery for lumbar disc hernia and
degeneration [26,30] but not after surgical removal of
molar teeth [31] or with a diagnosis of chronic wide
spread pain [34]. Experimentally, mechanical and ther-
mal pain protective effects of the SNP combination have
been found when measuring PPTs after induced hyper-
algesia (through freezing or applying capsaicin) of the
skin [32,35]. In our study, we found no correlation be-
tween the SNP combination and pressure pain sensitivity
on non-sensitized skin on the arm or leg. Nor did we
find any differences in pain measurements between
patients carrying or not carrying the SNP combination
in the sensitized vestibular mucosa [10-14]. The most
robust associations between GCH1 and pain responses
have been appearing in acute inflammatory pain models
[32,35]. Our findings are in line with the previously
reported lack of association of GCH1-variation with
chronic widespread pain, a predominantly female, long-
standing pain condition which shares over-lappingnd use of hormonal contraceptives (HCs) on pressure pain
tment (n = 38).
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specific effect of GCH1-variation on pain with less im-
pact on chronic pain disorders.
PVD differs from many other chronic pain disorders
since the patients are pain free in the absence of provo-
cation and the allodynia is restrained to a very limited
body area. However, our results verify previous findings
of higher general pain sensitivity among women with
PVD compared to controls, with both lower PPTs on the
arm and leg and a higher prevalence of other pain disor-
ders (i.e. higher bodily pain score) [15-18].
In this study there were no differences in pain meas-
urement between patients using or not using HCs. In
studies investigating the effect of HCs on pain sensitiv-
ity, the results have been inconsistent. Several studies
have failed to detect any differences in pain thresholds
or diffuse noxious inhibitory control (DNIC) -responses
between users and non-users of combined oral contra-
ceptives (COCs) [17,40,41]. Although, in a recent study
lower DNIC-responses in healthy COC users compared
to non-users in low estrogen phase were found, indicat-
ing less effective endogenous pain modulation in COC-
users but with only a weak correlation to endogenous
estrogen levels [42]. Moreover, an altered pain sensitivity
of the vestibular mucosa with decreased mechanical pain
thresholds among healthy COC-users has been reported
[43]. In our study, participants were examined during
follicular phase, day 3–13, when endogenous estrogen
levels are initially low but rising. The majority of partici-
pants with HCs used a combined pill containing both es-
trogen and various gestagens. In women with COCs the
endogenous estrogen levels are constantly low. However,
no measurements of sex hormone levels were performed
in this study.
The role of gene-environment interaction has gained
interest in recent years. This occurs when an environ-
mental effect is dependent on a person’s genotype or
vice versa. A limited number of studies focusing on
gene-environment interaction on pain sensitivity exist.
For example, desmopressin analgesia was shown to re-
sult from a three-way interaction between arginine vaso-
pressor receptor gene variant (AVPR1A), sex and level
of stress [44]. Several of the factors considered to con-
tribute to the etiology of PVD, such as recurrent Can-
dida infections and hormonal treatment, might have an
interactive effect with genetic variation. In order to in-
vestigate one such non-genetic factor possibly interact-
ing with GCH1-variation among women with PVD we
analyzed the interactive effect of GCH1-polymorphism
and HC use in relation to coital pain. Patients with
current treatment reported higher coital VAS pain score
as compared to patients with completed treatment and
therefore it was anticipated that an association would be
more evident in this group. We therefore analyzedpatients with current treatment as an entity of its own
and in this group we did find a correlation between the
studied SNP combination and lower pain scores in
patients not using HCs. Interestingly, in patients using
HCs the relationship was inversed with higher pain sen-
sitivity among carriers of the SNP combination. In the
clinic, a subgroup of women with PVD are improved or
even cured when hormonal contraceptive use is termi-
nated [7]. The explanation to this observation is not
known but it is inviting to speculate that it may result
from the influence of genetic differences on endogenous
pain modulation. According to our findings it is possible
that PVD patients carrying the studied SNP combination
would benefit the most from this intervention. However,
it has been shown that HCs may have a direct effect on
the vestibular mucosa [8,43] and it is not clear whether
the higher coital pain ratings seen among HC users is
caused by morphological changes or by hormonal effects
on endogenous pain modulation or an interaction of
both. Possibly the mucosal effects of HCs are greater
than the pain modulatory effect which could explain the
fact that among users of HCs there seem to be no pain
protective effect of the studied GCH1-SNP combination.
We also found a relation between the GCH1-SNP com-
bination, use of HCs and PPTs on the arm which
strengthens the idea of an interactive effect of these
variables.
Based on our findings of a GCH1-gene by HC inter-
action in relation to pain sensitivity, it can be speculated
that there would be a gene by sex interaction as well as
a gene by sex-steroids interaction. Studies have shown a
gene-sex interaction with pain sensitivity regarding
genes involved in the opioid and desmopressin systems
[44,45]. To our knowledge, this has not been studied
regarding GCH1. Most previous studies have partici-
pants of mixed sexes and the results have not been ana-
lyzed separately. Furthermore, a frequency of the studied
SNP combination of approximately 15% has been
reported in a normal Caucasian population of mixed
sexes [28,29]. In this material of young Swedish women
we found a carrier-frequency of the SNP combination
(homo- and heterozygous), among patients and controls,
of approximately 28%, this in line with findings by Dabo
and colleagues [36].
The exact role of this gene in human endogenous pain
modulation still needs to be clarified and genetic poly-
morphism in other genes possibly involved in pain
modulation in PVD remains a subject for future
research.
In the study design 100 participants in each group
were estimated to give sufficient power for this study
based on a method to optimize sample size in candidate
gene studies described by Belfer et al. [46]. Although an
even larger study group would have strengthen the
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inclusion criteria and there is strong evidence to support
the role of the GCH1-gene in human endogenous pain
modulation. Furthermore, by analyzing the gene poly-
morphism in correlation to continuous variables such as
pain measurements the power is increased. Regarding
the use of hormonal contraceptives one might argue that
a more homogenous group with respect to the hormonal
content would have been preferable, since in our mater-
ial the participants used both combined and progestogen
only methods. However a large variety of HCs are com-
monly used and inclusion of participants in this study
was based on the PVD diagnosis solely.
Conclusion
The results of this study gave no support to the hypoth-
esis that polymorphism in the GCH1-gene contributes
to the etiology of PVD. However, among patients cur-
rently receiving treatment an interaction effect of the
SNP combination of GCH1, previously identified as
pain-protective, and use of hormonal contraceptives on
pain sensitivity was found. These findings offer a pos-
sible explanation to the clinically known fact that some
PVD patients improve after cessation of hormonal con-
traceptives, indicating that PVD patients carrying the
studied GCH1-SNP combination would benefit from this
intervention.
Methods
Ninety-eight women with PVD were recruited. The in-
clusion criteria for patients were: age ≥ 18 years, PVD
defined as pain at vestibular contact and vaginal entry,
with duration of symptoms of ≥6 months based on the
initial exam at the time of diagnosis. The exclusion cri-
teria were: local infection or dermatological causes to
dyspareunia, major psychiatric or medical disease and
pregnancy. Controls consisted of 102 healthy women,
mostly medical students and hospital staff. The inclusion
criteria were age > 18 years, regular menstruation. Exclu-
sion criteria were: dyspareunia, major medical or psychi-
atric disease, use of regular analgesics or anti-depressants
and pregnancy. All participants received oral and written
information about the study and provided informed con-
sent and the study was approved by the local ethical
committee.
Clinical data
All participants were invited to a single testing session
carried out on days 3–13 of the menstrual cycle. A com-
prehensive questionnaire regarding psychosocial, med-
ical and gynecological history was filled out. Other
frequent bodily pain disorders were reported. The num-
ber of bodily pain disorders was used to create a bodily
pain score for each participant with a range from 0 – 5.Patients completed an additional questionnaire including
questions related to their PVD. For patients engaging in
vaginal intercourse, the intensity of coital pain during
the last month was scored on a Visual Analogue Scale
(VAS) with a range from 0 –100, where 0 represents no
pain and 100 represents the worst pain imaginable. Pres-
sure pain thresholds (PPTs) on the arm and leg was
measured using a pressure algometer (Somedic Sales
AB, Hörby, Sweden) with a disc shaped rubber top of
1 cm2. The arm was first tested, on the deltoid muscle,
3 cm proximal to the tendon insertion of the muscle.
Subsequently the leg was tested, on the anterior tibial
muscle, approximately 5 cm below and 3 cm lateral to
the tibial tuberosity. Testing was performed on the op-
posite side of the subjects reported dominant hand. The
device was applied perpendicularly to the skin and the
pressure was increased by 50–75 kPa/s. The participants
were asked to report the PPT, defined as when the sen-
sation changed from discomfort to pain by pushing a
button. The pressure, displayed digitally, was then regis-
tered. The measurement was repeated twice and the
mean value was registered. All participants were given a
careful explanation of the procedure and a training ses-
sion on the opposite arm before the testing started. Mea-
surements were carried out by the same examiner who
to this point was blinded to whether the participant
belonged to the patient or the control group as well as
to the participant’s genotype.
At this stage, the patient or control status was
revealed; PPTs in the vestibular mucosa were measured
in patients only, using vulvar algesiometers [47]. The
algesiometers consisted of cylindrical devices containing
metal springs of varying compression rates with a cotton
swab top. The set exerts a pressure ranging from 3–
1000 g. Two different areas of the vestibule was tested,
area A, in the anterior vestibule, close to the urethra and
area B, in the posterior vestibule, close to the opening of
the Bartholinás glands, both on the right side of the va-
ginal opening. The pressure was slowly and successively
increased until the participator orally reported the PPT.
The measurement was repeated twice and the mean
value was used for analysis. All subjects were given a
careful explanation of the procedure before the testing
started.
DNA isolation
Venous blood samples were collected in tubes containing
EDTA and the blood samples were stored at −70° until fur-
ther processing. The Magtration 12GC system (Precision
System Science, Chiba, Japan) and the MagazorbW DNA
Common Kit-200 (PSS, Chiba, Japan) were used for prepar-
ation of the total genomic DNA. From each sample 200 μl
whole blood was used and the final volume of the DNA ex-
tract was 100 μl. The concentration of the DNA was
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Techncologies Inc., Wilmington, DE, USA).
Genotyping of the SNPs in the GCH1
We focused on three SNPs to define the pain-protective
SNP combination of GCH1; dbSNP rs8007267G>A
(c.-9610 G>A), dbSNP rs3783641A>T (c343 + 8900A>
T) and dbSNP rs10483639C>G (c.*4279 >G). For the
analysis of these three SNP: s, we applied the TaqMan
SNP genotyping assay (Applied Biosystems, Foster City,
USA). Briefly, Applied Biosystems designed the primers
and the allele-specific probes. The assay included target-
specific PCR primers and TaqMan MGB probes labeled
with two special dyes, FAM and VIC. Genomic DNA
(5 ng), water, TaqMan Universal PCR master mix and
TaqMan genotyping assay mix was added to each well in
a 384-well plate, in a total volume of 5ul. The genotyp-
ing was carried out, using the ABI7900HT genetic detec-
tion system (Applied Biosystems, Foster City, USA)
according to the manufacturersá instructions, with the
following amplification protocol: 10 min at 95°C and
40 cycles of 15 s at 92°C and 1 min at 60°C.
Statistics
The Statistica program (version 10, StatSoft Inc., Tulsa,
OK, USA) and the Statistical package for the Social
Sciences program (version 20, SPSS Inc., Chicago, IL,
USA) were used. In comparisons of pain sensitivity be-
tween groups the analysis of variance (ANOVA)-test was
used. For ordinal data the non parametric equivalents
Kruskal-Wallis and the Mann–Whitney U-test were
used respectively and for SNP frequencies the Chi2-test.
To analyze a possible interaction between GCH1-SNP
combination and use of HCs in relation to pain sensitiv-
ity we used general linear regression models (GLM) with
main effects of GCH1-SNP combination and use of HCs
as well as interaction effects of GCH1-SNP combination
and HCs together. A significance level of p < 0.05 was
used for all statistical tests and a confidence interval of
95% for the logistic regression analyses.
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